LEIDEN, NETHERLANDS--(Marketwire - February 12, 2008) - Total revenue and other operating income grew by more than 50% to EUR 213.1 million, compared to EUR 140.9 million in 2006. Successful Quinvaxem™ launch drives strong autonomous growth. Strong operating cash flow of EUR 51.5 million in the fourth quarter and EUR 22.2 million for the year compared to a negative EUR 54.0 million in 2006. 2008 full year guidance: total revenue and other operating income growth of 20% in constant currencies ; higher margins; positive cash flow.
